Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
Torrisi R, Jacobs F, Miggiano C, De Sanctis R, Santoro A. Torrisi R, et al. Among authors: santoro a. Drugs Context. 2023 Mar 6;12:2022-12-2. doi: 10.7573/dic.2022-12-2. eCollection 2023. Drugs Context. 2023. PMID: 36926051 Free PMC article. Review.
Clinical Review on the Management of Breast Cancer Visceral Crisis.
Benvenuti C, Gaudio M, Jacobs F, Saltalamacchia G, De Sanctis R, Torrisi R, Santoro A, Zambelli A. Benvenuti C, et al. Among authors: santoro a. Biomedicines. 2023 Apr 3;11(4):1083. doi: 10.3390/biomedicines11041083. Biomedicines. 2023. PMID: 37189701 Free PMC article. Review.
Opportunities and Challenges of Synthetic Data Generation in Oncology.
Jacobs F, D'Amico S, Benvenuti C, Gaudio M, Saltalamacchia G, Miggiano C, De Sanctis R, Della Porta MG, Santoro A, Zambelli A. Jacobs F, et al. Among authors: santoro a. JCO Clin Cancer Inform. 2023 Aug;7:e2300045. doi: 10.1200/CCI.23.00045. JCO Clin Cancer Inform. 2023. PMID: 37535875 Free article. Review.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: santoro a. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.
Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, Tiberio P, Manara SAAM, Solferino A, Santoro A, De Sanctis R. Borroni RG, et al. Among authors: santoro a. Oncologist. 2024 Jan 18:oyae004. doi: 10.1093/oncolo/oyae004. Online ahead of print. Oncologist. 2024. PMID: 38242689 Free article.
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel.
Lalioti A, Verzeletti L, Tiberio P, Gerosa R, Gaudio M, Saltalamacchia G, Pastore M, Zambelli A, Santoro A, De Sanctis R. Lalioti A, et al. Among authors: santoro a. Cancers (Basel). 2024 Jan 11;16(2):306. doi: 10.3390/cancers16020306. Cancers (Basel). 2024. PMID: 38254795 Free PMC article. Review.
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: santoro a. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
3,017 results